Epigenetic Drugs: from Cancer to Aging, Q2 2022
This 70-page “Epigenetic Drugs Q2 2022” report aims to provide a comprehensive overview of the current state of the epigenetic drugs market and research. The aim of this report is to provide insights into the diversity of possible epigenetic targets, mechanisms of their action and possibilities of combining epigenetic drugs with other therapies in treating cancer and other diseases. This overview highlights trends and insights in a form of informative mind maps and infographics as well as benchmarks the performance of key players that form the space and relations within the industry. The current release includes insights about 80 companies that develop epigenetic drugs and 65 drugs that are in clinical trials or were approved by FDA.